American Association for Cancer Research
Browse
15417786mcr170433-sup-187650_2_supp_4528725_p34ll2.pdf (214.53 kB)

Supplementary Figure S6 from Functional Toll-like Receptor 4 Overexpression in Papillary Thyroid Cancer by MAPK/ERK–Induced ETS1 Transcriptional Activity

Download (214.53 kB)
journal contribution
posted on 2023-04-03, 16:46 authored by Victoria Peyret, Magalí Nazar, Mariano Martín, Amado A. Quintar, Elmer A. Fernandez, Romina C. Geysels, Cesar S. Fuziwara, María M. Montesinos, Cristina A. Maldonado, Pilar Santisteban, Edna T. Kimura, Claudia G. Pellizas, Juan P. Nicola, Ana M. Masini-Repiso

Etsd binding site is crucial for TLR4 gene transcription in response to conditionally induced HRasG12V and RET/PTC3 signaling.

Funding

Agencia Nacional de Promocion Científica y Tecnologica

Ministerio de Economía y Competitividad de España – Fondo Europeo de Desarrollo Regional

Fundacion Española contra el Cancer

History

ARTICLE ABSTRACT

Emerging evidence suggests that unregulated Toll-like receptor (TLR) signaling promotes tumor survival signals, thus favoring tumor progression. Here, the mechanism underlying TLR4 overexpression in papillary thyroid carcinomas (PTC) mainly harboring the BRAFV600E mutation was studied. TLR4 was overexpressed in PTC compared with nonneoplastic thyroid tissue. Moreover, paired clinical specimens of primary PTC and its lymph node metastasis showed a significant upregulation of TLR4 levels in the metastatic tissues. In agreement, conditional BRAFV600E expression in normal rat thyroid cells and mouse thyroid tissue upregulated TLR4 expression levels. Furthermore, functional TLR4 expression was demonstrated in PTC cells by increased NF-κB transcriptional activity in response to the exogenous TLR4-agonist lipopolysaccharide. Of note, The Cancer Genome Atlas data analysis revealed that BRAFV600E-positive tumors with high TLR4 expression were associated with shorter disease-free survival. Transcriptomic data analysis indicated a positive correlation between TLR4 expression levels and MAPK/ERK signaling activation. Consistently, chemical blockade of MAPK/ERK signaling abrogated BRAFV600E-induced TLR4 expression. A detailed study of the TLR4 promoter revealed a critical MAPK/ERK–sensitive Ets-binding site involved in BRAFV600E responsiveness. Subsequent investigation revealed that the Ets-binding factor ETS1 is critical for BRAFV600E-induced MAPK/ERK signaling-dependent TLR4 gene expression. Together, these data indicate that functional TLR4 overexpression in PTCs is a consequence of thyroid tumor-oncogenic driver dysregulation of MAPK/ERK/ETS1 signaling.Implications: Considering the participation of aberrant NF-κB signaling activation in the promotion of thyroid tumor growth and the association of high TLR4 expression with more aggressive tumors, this study suggests a prooncogenic potential of TLR4 downstream signaling in thyroid tumorigenesis. Mol Cancer Res; 16(5); 833–45. ©2018 AACR.